Tarlatamab is an investigational study drug that is being tested in clinical studies to see if it can help patients with either of two kinds of neuroendocrine cancer: small cell lung cancer (SCLC) or neuroendocrine prostate cancer (NEPC).
Tarlatamab is a type of drug called a bispecific T-cell engager, or BiTE® molecule, that has two key parts: a part that attaches to your T-cells, a type of immune cell, and a part that attaches to the cancer cells.
Tarlatamab is a type of immunotherapy that works differently than standard chemotherapy. It is designed to help the body's immune cells find, attach to, and attack cancer cells.
Tarlatamab is an investigational study drug that is being used only in clinical studies that are testing its safety and effectiveness in patients with cancer.